Mark James Galliguez, PA

Mark Galliguez practices at Citymd Urgent Care in New York, New York.

Mark Galliguez's NPI, 1871734566, was assigned on March 10, 2009. Mark Galliguez holds New York license 013177.

Mark Galliguez's primary practice is Citymd Urgent Care, at 617 W 181st St, New York, NY 10033 in New York County. The practice phone is (516) 783-4600.

Mark Galliguez's primary practice is Citymd Urgent Care in New York, New York. Mark Galliguez is also affiliated with NYC Health + Hospitals/Jacobi. The medical group on file is Weill Cornell Physicians. Dmand AI also links Mark Galliguez to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Galliguez practices. Vendor and product names are available with a free account.

Physician assistant is Mark Galliguez's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Mark Galliguez is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Mark Galliguez is licensed in New York.

Dmand AI lists asthma, broken or dislocated ankle/ or foot, chronic obstructive pulmonary disease (COPD), conjunctivitis, head wound, joint pain, rash and swimmer's ear among the conditions Mark Galliguez treats.

CMS data shows 109 Medicare services from Mark Galliguez across 3 procedure codes in 2024, for 96 Medicare patients. Medicare paid $6,743 for them. Every service was in an office.

CMS counts 96 Medicare patients who saw Mark Galliguez in 2024. The largest group is 65 to 74, with 36 patients. 61% of them have high cholesterol, and 59% have high blood pressure. 25% are also on Medicaid. Their average risk score is 1.09, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mark Galliguez's median patient age at 34, with 73% women.

In 2024, Mark Galliguez wrote 349 Medicare Part D claims for 255 patients. 92% of them were for generic drugs. CMS names the drug for 178 of them, across 8 drugs with 11 or more claims each, at $992 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Mark Galliguez for performance year 2024, reported as part of a group. Mark Galliguez accepts Medicare assignment, so Medicare's approved amount is taken as full payment.